Siever LJ y otros "Depressive response to physostigmine challenge in borderline personality disorder patients". [6]Neuropsychopharmacology 1997 Oct; 17(4):264-73
BLACK, Dw et al.Relationship of sex to symptom severity, psychiatric comorbidity, and health care utilization in 163 subjects with borderline personality disorder." [15]Compr Psychiatry. 2007 Sep-Oct;48(5):406-12. Epub 2007 Jul 5
Stoffers, Jutta; Birgit A Völlm, Gerta Rücker, Antje Timmer, Nick Huband, Klaus Lieb (2010). «Pharmacological interventions for borderline personality disorder». Cochrane Database of Systematic Reviews (Online)6: CD005653. ISSN1469-493X. doi:10.1002/14651858.CD005653.pub2.La referencia utiliza el parámetro obsoleto |coautores= (ayuda)
lipidworld.com
Sieswerda,LE y otros, "Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?" [18], Lipids Health Dis. 2007 Sep 18;6:21 PMID 17877810
Shumyatsky GP, Tsvetkov E, Malleret G, Vronskaya S, Hatton M, Hampton L, Battey JF, Dulac C, Kandel ER, Bolshakov VY., "Identification of a signaling network in lateral nucleus of amygdala important for inhibiting memory specifically related to learned fear.", Cell. 2002 Dec 13;111(6):905-18. PMID 12526815
Pape HC, Stork O., Genes and mechanisms in the amygdala involved in the formation of fear memory.Ann N Y Acad Sci. 2003 Apr;985:92-105.PMID 12724151
Pape HC, Narayanan RT, Smid J, Stork O, Seidenbecher T., Theta activity in neurons and networks of the amygdala related to long-term fear memory., Hippocampus. 2005;15(7):874-80. PMID 16158424
Huang YY, Kandel ER., 5-Hydroxytryptamine induces a protein kinase A/mitogen-activated protein kinase-mediated and macromolecular synthesis-dependent late phase of long-term potentiation in the amygdala. J Neurosci. 2007 Mar 21;27(12):3111-9.PMID 17376972
"Association between the serotonin transporter gene..." [3] Pascual J, Soler et al. en Actas Esp Psiquiatr. 2007 Nov;35(6):382-386.
Ni, X et al. "Monoamine oxidase a gene is associated with borderline personality disorder" [5]Psychiatr Genet. 2007 Jun;17(3):153-7
JOYCE PR, KENNEDY MA y otros: "A dopamine transporter polymorphism is a risk factor for borderline personality disorder in depressed patients", Psychol Med. 2006 Jun; 36(6):807-13 PMID 16623961
Pogarell O. et al. "EEG-vigilance differences between patients with borderline personality disorder, patients with obsessive-compulsive disorder and healthy controls". Eur Arch Psychiatry Clin Neurosci, 2007 Nov 7 PMID 17990048
De la Fuente JM, Tugendhaft P, Mavroudakis N., "Electroencephalographic abnormalities in borderline personality disorder". Psychiatry Res. 1998 Feb 9;77(2):131-8 PMID 9541149
Minzenberg MJ, Fan J, New AS, Tang CY, Siever LJ. "Frontolimbic structural changes in borderline personality disorder". [7]J Psychiatr Res. 2007 Sep 6;
Bremner JD et al."Hippocampal and amygdalar volumes in dissociative identity disorder." [8]Am J Psychiatry. 2006 Apr;163(4):630-6 PMID 16585437
Buchsbaum MS. et al. "Reduced anterior and posterior cingulate gray matter in borderline personality disorder."[9]Biol Psychiatry. 2005 Oct 15;58(8):614-23
HIGLEY JD y otros: Maternal absence and stability of individual differences in CSF 5-HIAA concentrations in rhesus monkey infants. Am J Psychiatry. 2005 Sep;162(9):1658-64 PMID 16135625
MEANEY, MJ y KAFFMAN, A: "Neurodevelopmental sequelae of postnatal maternal care in rodents: clinical and research implications of molecular insights." J Child Psychol Psychiatry. 2007 Mar-Apr;48(3-4):224-44 PMID 17355397
MEANEY MJ y otros: Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat Front Neuroendocrinol. 2005 Oct-Dec;26(3-4):139-62 PMID 17301183
MEANEY MJ y otros: "Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat" Front Neuroendocrinol. 2005 Oct-Dec;26(3-4):139-62 PMID 16303171
TREMBLAY R y otros: "Nonmaternal care in infancy and emotional/behavioral difficulties at 4 years old: Moderation by family risk characteristics." Dev Psychol. 2008 Jan;44(1):155-68 PMID 18194014
Austin MA, Riniolo TC, Porges SW. "Borderline personality disorder and emotion regulation: insights from the Polyvagal Theory". Brain Cogn. 2007 Oct;65(1):69-76 PMID 17659821
Carrasco JL, Díaz-Marsá M, Pastrana JI, Molina R, Brotons L, López-Ibor MI, López-Ibor JJ.,"Hypothalamic-pituitary-adrenal axis response in borderline personality disorder without post-traumatic features". Br J Psychiatry. 2007 Apr;190:357-8 PMID 17401044
Driessen M. y otros "Stability of the dexamethasone suppression test in borderline personality disorder with and without comorbid PTSD: a one-year follow-up study." J Clin Psychol. 2007 Sep; 63(9):843-50 PMID 17674401
Riemann, D: "Increased delta power and discrepancies in objective and subjective sleep measurements in borderline personality disorder.", J Psychiatr Res. 2005 Sep;39(5):489-98 PMID 15992558
Lammers, CH: "Declarative and procedural memory consolidation during sleep in patients with borderline personality disorder.", J Psychiatr Res. 2007 Aug 15 PMID 17706671
Muir, WJ: "Auditory P300 in borderline personality disorder and schizophrenia.", Arch Gen Psychiatry. 1987 Jul;44(7):645-50 PMID 3606330
St Clair DM. y otros: "Auditory P300 does not differentiate borderline personality disorder from schizotypal personality disorder.", Biol Psychiatry. 1989 Dec;26(8):766-74 PMID 2590690
Mann JJ, "The relationship of platelet 5-HT2 receptor indices to major depressive disorder, personality traits, and suicidal behavior." Biol Psychiatry. 1994 Mar 1;35(5):295-308 PMID 8011798
Van Kempen GM, "Platelet serotonin, monoamine oxidase activity, and [3H]paroxetine binding related to impulsive suicide attempts and borderline personality disorder.", Biol Psychiatry. 1998 May 15;43(10):740-6 PMID 9606528
Nair, NP: Impaired platelet [3H]paroxetine binding in female patients with borderline personality disorder, 2005 Nov;182(3):447-51 PMID 16052363
Altman, EG y otros: "EEG sleep, lithium transport, dexamethasone suppression, and monoamine oxidase activity in borderline personality disorder.", Psychiatry Res. 1988 Jul;25(1):19-30 PMID 3217463
Zanarini MC y otros Gender differences in borderline personality disorder: findings from the Collaborative Longitudinal Personality Disorders Study[14] Compr Psychiatry. 2003 Jul-Aug;44(4):284-92
Bradley R, Zittel Conklin C, Westen D.[16] "The borderline personality diagnosis in adolescents: gender differences and subtypes." J Child Psychol Psychiatry. 2005 Sep;46(9):1006-19
Ren-Patterson RF, Cochran LW, Holmes A, Lesch KP, Lu B, Murphy DL: "Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies.", Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):755-80. Epub 2006 Sep 22 PMID 17029036
BOHUS, M y otros: "Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder" The British Journal of Psychiatry (2008) 192: 118-123. doi: 10.1192/bjp.bp.107.035782 PMID 18245028
Links PS, Heslegrave R, van Reekum R: "Prospective follow-up study of borderline personality disorder: prognosis, prediction of outcome, and Axis II comorbidity", Can J Psychiatry. 1998 Apr;43(3):265-70 PMID 9561315
Gundersson, JG; Zanarini, MC y otros: "Predictors of 2-year outcome for patients with borderline personality disorder", Am J Psychiatry. 2006 May;163(5):822-6 PMID 16648322
Zanarini MC, Frankenburg FR, Hennen J, Reich DB y Silk KR: "Prediction of the 10-year course of borderline personality disorder", Am J Psychiatry. 2006 May;163(5):827-32 PMID 16648323
Sugarman, A (2006). «Mentalization, insightfulness, and therapeutic action. The importance of mental organization». International Journal of Psychoanalysis87 (4): 965-87. PMID16877247.|fechaacceso= requiere |url= (ayuda)
Kaplan, P y otros:"Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study." Am J Psychiatry. 2006 May;163(5):833-8 PMID 16648324
Suppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B: "Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder.", J Affect Disord. 2007 Sep 26, PMID 17904226
Ferreri MM, Loze JY, Rouillon F, Limosin F: "Clozapine treatment of a borderline personality disorder with severe self-mutilating behaviours." Eur Psychiatry. 2004 May;19(3):177-8 PMID 15158928
Chengappa KN, Ebeling T, Kang JS, Levine J, Parepally H: "Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder". J Clin Psychiatry. 1999 Jul;60(7):477-84 PMID 1045380
Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R: "Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens." Pharmacogenomics J. 2007 Oct;7(5):325-32. Epub 2006 Oct 17 PMID 17001352
Zanarini MC, Frankenburg FR: "Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study", J Clin Psychiatry. 2001 Nov; 62(11):849-54 PMID 11775043
George Nurnberg y otros: "Olanzapine versus placebo in the treatment of borderline personality disorder." J Clin Psychiatry. 2004 Jan;65(1):104-9 PMID 14744178
Zanarini MC, Frankenburg FR, Parachini EA: "A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.", J Clin Psychiatry. 2004 Jul;65(7):903-7 PMID 15291677
Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Álvarez E, Pérez V: "Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder"., Am J Psychiatry. 2005 Jun;162(6):1221-4 PMID 15930077
Bellino S, Paradiso E, Bogetto F: "Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.", J Clin Psychiatry. 2006 Jul;67(7):1042-6, PMID 16889446
Perrella C, Carrus D, Costa E, Schifano F: "Quetiapine for the treatment of borderline personality disorder; an open-label study.", Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):158-63, PMID 17045720
Rocca P, Marchiaro L, Cocuzza E, Bogetto F: "Treatment of borderline personality disorder with risperidone"., J Clin Psychiatry. 2002 Mar;63(3):241-4 PMID 11926724
Egger C., "Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study." J Clin Psychopharmacol. 2006 Feb;26(1):61-6. PMID 16415708
Bellino S, Paradiso E, Bogetto F., "Oxcarbazepine in the treatment of borderline personality disorder: a pilot study.", J Clin Psychiatry. 2005 Sep;66(9):1111-5 PMID 16187767
Bolm T, Piegler T., Naltrexone in the treatment of dissociative disorders--reflections with regard to a comprehensive therapeutic concept of borderline disordersPsychiatr Prax. 2001 Jul;28(5):214-8 PMID 11479827
Lieb K. y otros, "Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder." J Clin Psychiatry. 2004 Oct;65(10):1414-9 PMID 15491247
Sieswerda,LE y otros, "Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?" [18], Lipids Health Dis. 2007 Sep 18;6:21 PMID 17877810
Tebartz van Elst y otros, "Corpus callosum abnormalities in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder",[12] J Psychiatry Neurosci. 2007 November; 32(6): 417–422.
por MedlinePlus Medicinas (agosto de 2007). «Amitriptilina». Medicinas y Suplementos. Consultado el 1 de febrero de 2008.La referencia utiliza el parámetro obsoleto |mes= (ayuda)
Campling, P. (2001). “Therapeutic communities”. Advances in Psychiatric Treatment (7): 365-372. Visitado el 2007-09-23.
sciencedirect.com
Ni, X et al. "Serotonin 2A receptor gene is associated with personality traits, but not to disorder, in patients with borderline personality disorder." [4]Archivado el 6 de marzo de 2010 en Wayback Machine. Neurosci Lett. 2006 Nov 20;408(3):214-9. Epub 2006 Sep 26.
Tebartz L y otros: "Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder.", Neuroscience Letters 417,1Archivado el 23 de diciembre de 2008 en Wayback Machine.
Garner, B et al. "Pituitary volume in teenagers with first-presentation borderline personality disorder"[10]Archivado el 6 de marzo de 2010 en Wayback Machine. Psychiatry Res. 2007 Oct 11
SEVERENS JL "The cost of borderline personality disorder: societal cost of illness in BPD-patients."[19]Archivado el 23 de diciembre de 2008 en Wayback Machine. Eur Psychiatry. 2007 Sep;22(6):354-61. Epub 2007 Jun 4.
Svenn Torgersen; Einar Kringlen y Victoria CramerThe Prevalence of Personality Disorders in a Community Sample[1], Arch Gen Psychiatry. 2001;58:590-596]
Estadísticas de pacientes hospitalizados en DSM-IV[2]Archivado el 14 de noviembre de 2020 en Wayback Machine.
Ni, X et al. "Serotonin 2A receptor gene is associated with personality traits, but not to disorder, in patients with borderline personality disorder." [4]Archivado el 6 de marzo de 2010 en Wayback Machine. Neurosci Lett. 2006 Nov 20;408(3):214-9. Epub 2006 Sep 26.
Tebartz L y otros: "Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder.", Neuroscience Letters 417,1Archivado el 23 de diciembre de 2008 en Wayback Machine.
Garner, B et al. "Pituitary volume in teenagers with first-presentation borderline personality disorder"[10]Archivado el 6 de marzo de 2010 en Wayback Machine. Psychiatry Res. 2007 Oct 11
SEVERENS JL "The cost of borderline personality disorder: societal cost of illness in BPD-patients."[19]Archivado el 23 de diciembre de 2008 en Wayback Machine. Eur Psychiatry. 2007 Sep;22(6):354-61. Epub 2007 Jun 4.
